Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients

Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging

David A. Richard, Sanda Nousia-Arvanitakis, Veronika Sollich, Barbara J. Hampel, Bernd Sommerauer, Urs B. Schaad, A. Sardet, S. Brömme, E. Klöditz, T. Lietz, R. Schille, H. G. Posselt, S. Noll, V. Sollich, T. Zimmermann, H. Bärmeier-Wasmuth, U. Wahn, A. Weber, K. Magdorf, F. Wacker & 20 others J. Tröger, M. Lyle, A. Schmidt, I. Preuss, C. Krasemann, P. Nikolaidis, A. Peonides, S. Skalidopoulos, G. Sotiriadis, K. Gyurkovits, K. Bolbas, J. Rivlin, G. Mastella, M. Cipolli, P. Trogu, C. Barreto, E. Lara, J. Egner, M. Hauptmann, J. Wedgwood

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background. More data on the efficacy and safety of ciprofloxacin in pediatric cystic fibrosis patients are needed. Methods. One hundred eight pediatric cystic fibrosis patients (ages 5 to 17 years) with acute bronchopulmonary exacerbations entered a randomized multicenter trial designed to compare the safety and efficacy of antipseudomonas therapy with oral ciprofloxacin (15 mg/kg twice daily; maximum dosage 750 mg twice daily) or intravenous ceftazidime plus tobramycin (CAZ/TM) for 14 days. Results. Clinical improvement was observed in 93% of patients treated with oral ciprofloxacin and in 96% of those receiving parenteral therapy. Transient suppression of Pseudomonas aeruginosa was achieved in 63% of patients at the end of the course of iv CAZ/TM therapy and in 24% receiving ciprofloxacin. Ultrasound examination and nuclear magnetic resonance imaging scans showed no evidence of cartilage toxicity in any of the ciprofloxacin-treated patients. Musculoskeletal adverse events were reported with similar frequency in the two groups of patients (7% in the group receiving ciprofloxacin therapy and 11% in the IV CAZ/TM group). The only sustained musculoskeletal symptom was a case of synovitis in a patient receiving parenteral CAZ/TM. Conclusion. Ciprofloxacin thus appears to be safe and effective for use in young patients with bronchopulmonary exacerbation of cystic fibrosis.

Original languageEnglish
Pages (from-to)572-578
Number of pages7
JournalPediatric Infectious Disease Journal
Volume16
Issue number6
DOIs
Publication statusPublished - Jun 1997

Fingerprint

Tobramycin
Ceftazidime
Ciprofloxacin
Cystic Fibrosis
Ultrasonography
Magnetic Resonance Imaging
Pediatrics
Safety
Synovitis
Therapeutics
Pseudomonas aeruginosa
Multicenter Studies
Cartilage
Magnetic Resonance Spectroscopy

Keywords

  • Antipseudomonas
  • Ciprofloxacin
  • Cystic fibrosis
  • Pediatrics
  • Skeletal toxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients : Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. / Richard, David A.; Nousia-Arvanitakis, Sanda; Sollich, Veronika; Hampel, Barbara J.; Sommerauer, Bernd; Schaad, Urs B.; Sardet, A.; Brömme, S.; Klöditz, E.; Lietz, T.; Schille, R.; Posselt, H. G.; Noll, S.; Sollich, V.; Zimmermann, T.; Bärmeier-Wasmuth, H.; Wahn, U.; Weber, A.; Magdorf, K.; Wacker, F.; Tröger, J.; Lyle, M.; Schmidt, A.; Preuss, I.; Krasemann, C.; Nikolaidis, P.; Peonides, A.; Skalidopoulos, S.; Sotiriadis, G.; Gyurkovits, K.; Bolbas, K.; Rivlin, J.; Mastella, G.; Cipolli, M.; Trogu, P.; Barreto, C.; Lara, E.; Egner, J.; Hauptmann, M.; Wedgwood, J.

In: Pediatric Infectious Disease Journal, Vol. 16, No. 6, 06.1997, p. 572-578.

Research output: Contribution to journalArticle

Richard, DA, Nousia-Arvanitakis, S, Sollich, V, Hampel, BJ, Sommerauer, B, Schaad, UB, Sardet, A, Brömme, S, Klöditz, E, Lietz, T, Schille, R, Posselt, HG, Noll, S, Sollich, V, Zimmermann, T, Bärmeier-Wasmuth, H, Wahn, U, Weber, A, Magdorf, K, Wacker, F, Tröger, J, Lyle, M, Schmidt, A, Preuss, I, Krasemann, C, Nikolaidis, P, Peonides, A, Skalidopoulos, S, Sotiriadis, G, Gyurkovits, K, Bolbas, K, Rivlin, J, Mastella, G, Cipolli, M, Trogu, P, Barreto, C, Lara, E, Egner, J, Hauptmann, M & Wedgwood, J 1997, 'Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging', Pediatric Infectious Disease Journal, vol. 16, no. 6, pp. 572-578. https://doi.org/10.1097/00006454-199706000-00007
Richard, David A. ; Nousia-Arvanitakis, Sanda ; Sollich, Veronika ; Hampel, Barbara J. ; Sommerauer, Bernd ; Schaad, Urs B. ; Sardet, A. ; Brömme, S. ; Klöditz, E. ; Lietz, T. ; Schille, R. ; Posselt, H. G. ; Noll, S. ; Sollich, V. ; Zimmermann, T. ; Bärmeier-Wasmuth, H. ; Wahn, U. ; Weber, A. ; Magdorf, K. ; Wacker, F. ; Tröger, J. ; Lyle, M. ; Schmidt, A. ; Preuss, I. ; Krasemann, C. ; Nikolaidis, P. ; Peonides, A. ; Skalidopoulos, S. ; Sotiriadis, G. ; Gyurkovits, K. ; Bolbas, K. ; Rivlin, J. ; Mastella, G. ; Cipolli, M. ; Trogu, P. ; Barreto, C. ; Lara, E. ; Egner, J. ; Hauptmann, M. ; Wedgwood, J. / Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients : Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. In: Pediatric Infectious Disease Journal. 1997 ; Vol. 16, No. 6. pp. 572-578.
@article{c6d6a239adb24fe8aa5c68c31dfb580d,
title = "Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging",
abstract = "Background. More data on the efficacy and safety of ciprofloxacin in pediatric cystic fibrosis patients are needed. Methods. One hundred eight pediatric cystic fibrosis patients (ages 5 to 17 years) with acute bronchopulmonary exacerbations entered a randomized multicenter trial designed to compare the safety and efficacy of antipseudomonas therapy with oral ciprofloxacin (15 mg/kg twice daily; maximum dosage 750 mg twice daily) or intravenous ceftazidime plus tobramycin (CAZ/TM) for 14 days. Results. Clinical improvement was observed in 93{\%} of patients treated with oral ciprofloxacin and in 96{\%} of those receiving parenteral therapy. Transient suppression of Pseudomonas aeruginosa was achieved in 63{\%} of patients at the end of the course of iv CAZ/TM therapy and in 24{\%} receiving ciprofloxacin. Ultrasound examination and nuclear magnetic resonance imaging scans showed no evidence of cartilage toxicity in any of the ciprofloxacin-treated patients. Musculoskeletal adverse events were reported with similar frequency in the two groups of patients (7{\%} in the group receiving ciprofloxacin therapy and 11{\%} in the IV CAZ/TM group). The only sustained musculoskeletal symptom was a case of synovitis in a patient receiving parenteral CAZ/TM. Conclusion. Ciprofloxacin thus appears to be safe and effective for use in young patients with bronchopulmonary exacerbation of cystic fibrosis.",
keywords = "Antipseudomonas, Ciprofloxacin, Cystic fibrosis, Pediatrics, Skeletal toxicity",
author = "Richard, {David A.} and Sanda Nousia-Arvanitakis and Veronika Sollich and Hampel, {Barbara J.} and Bernd Sommerauer and Schaad, {Urs B.} and A. Sardet and S. Br{\"o}mme and E. Kl{\"o}ditz and T. Lietz and R. Schille and Posselt, {H. G.} and S. Noll and V. Sollich and T. Zimmermann and H. B{\"a}rmeier-Wasmuth and U. Wahn and A. Weber and K. Magdorf and F. Wacker and J. Tr{\"o}ger and M. Lyle and A. Schmidt and I. Preuss and C. Krasemann and P. Nikolaidis and A. Peonides and S. Skalidopoulos and G. Sotiriadis and K. Gyurkovits and K. Bolbas and J. Rivlin and G. Mastella and M. Cipolli and P. Trogu and C. Barreto and E. Lara and J. Egner and M. Hauptmann and J. Wedgwood",
year = "1997",
month = "6",
doi = "10.1097/00006454-199706000-00007",
language = "English",
volume = "16",
pages = "572--578",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients

T2 - Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging

AU - Richard, David A.

AU - Nousia-Arvanitakis, Sanda

AU - Sollich, Veronika

AU - Hampel, Barbara J.

AU - Sommerauer, Bernd

AU - Schaad, Urs B.

AU - Sardet, A.

AU - Brömme, S.

AU - Klöditz, E.

AU - Lietz, T.

AU - Schille, R.

AU - Posselt, H. G.

AU - Noll, S.

AU - Sollich, V.

AU - Zimmermann, T.

AU - Bärmeier-Wasmuth, H.

AU - Wahn, U.

AU - Weber, A.

AU - Magdorf, K.

AU - Wacker, F.

AU - Tröger, J.

AU - Lyle, M.

AU - Schmidt, A.

AU - Preuss, I.

AU - Krasemann, C.

AU - Nikolaidis, P.

AU - Peonides, A.

AU - Skalidopoulos, S.

AU - Sotiriadis, G.

AU - Gyurkovits, K.

AU - Bolbas, K.

AU - Rivlin, J.

AU - Mastella, G.

AU - Cipolli, M.

AU - Trogu, P.

AU - Barreto, C.

AU - Lara, E.

AU - Egner, J.

AU - Hauptmann, M.

AU - Wedgwood, J.

PY - 1997/6

Y1 - 1997/6

N2 - Background. More data on the efficacy and safety of ciprofloxacin in pediatric cystic fibrosis patients are needed. Methods. One hundred eight pediatric cystic fibrosis patients (ages 5 to 17 years) with acute bronchopulmonary exacerbations entered a randomized multicenter trial designed to compare the safety and efficacy of antipseudomonas therapy with oral ciprofloxacin (15 mg/kg twice daily; maximum dosage 750 mg twice daily) or intravenous ceftazidime plus tobramycin (CAZ/TM) for 14 days. Results. Clinical improvement was observed in 93% of patients treated with oral ciprofloxacin and in 96% of those receiving parenteral therapy. Transient suppression of Pseudomonas aeruginosa was achieved in 63% of patients at the end of the course of iv CAZ/TM therapy and in 24% receiving ciprofloxacin. Ultrasound examination and nuclear magnetic resonance imaging scans showed no evidence of cartilage toxicity in any of the ciprofloxacin-treated patients. Musculoskeletal adverse events were reported with similar frequency in the two groups of patients (7% in the group receiving ciprofloxacin therapy and 11% in the IV CAZ/TM group). The only sustained musculoskeletal symptom was a case of synovitis in a patient receiving parenteral CAZ/TM. Conclusion. Ciprofloxacin thus appears to be safe and effective for use in young patients with bronchopulmonary exacerbation of cystic fibrosis.

AB - Background. More data on the efficacy and safety of ciprofloxacin in pediatric cystic fibrosis patients are needed. Methods. One hundred eight pediatric cystic fibrosis patients (ages 5 to 17 years) with acute bronchopulmonary exacerbations entered a randomized multicenter trial designed to compare the safety and efficacy of antipseudomonas therapy with oral ciprofloxacin (15 mg/kg twice daily; maximum dosage 750 mg twice daily) or intravenous ceftazidime plus tobramycin (CAZ/TM) for 14 days. Results. Clinical improvement was observed in 93% of patients treated with oral ciprofloxacin and in 96% of those receiving parenteral therapy. Transient suppression of Pseudomonas aeruginosa was achieved in 63% of patients at the end of the course of iv CAZ/TM therapy and in 24% receiving ciprofloxacin. Ultrasound examination and nuclear magnetic resonance imaging scans showed no evidence of cartilage toxicity in any of the ciprofloxacin-treated patients. Musculoskeletal adverse events were reported with similar frequency in the two groups of patients (7% in the group receiving ciprofloxacin therapy and 11% in the IV CAZ/TM group). The only sustained musculoskeletal symptom was a case of synovitis in a patient receiving parenteral CAZ/TM. Conclusion. Ciprofloxacin thus appears to be safe and effective for use in young patients with bronchopulmonary exacerbation of cystic fibrosis.

KW - Antipseudomonas

KW - Ciprofloxacin

KW - Cystic fibrosis

KW - Pediatrics

KW - Skeletal toxicity

UR - http://www.scopus.com/inward/record.url?scp=0030972776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030972776&partnerID=8YFLogxK

U2 - 10.1097/00006454-199706000-00007

DO - 10.1097/00006454-199706000-00007

M3 - Article

VL - 16

SP - 572

EP - 578

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 6

ER -